DPP-IV-resistant, long-acting oxyntomodulin derivatives

Journal of Peptide Science

Volumn 17, Issue 4, 2011, Pages 270-280

  Santoprete, Alessia ^a   Capitò, Elena ^a,b   Carrington, Paul E ^c   Pocai, Alessandro ^c   Finotto, Marco ^a   Langella, Annunziata ^a,d   Ingallinella, Paolo ^a,e   Zytko, Karolina ^a   Bufali, Simone ^a,f   Cianetti, Simona ^a,f   Veneziano, Maria ^a   Bonelli, Fabio ^a   Zhu, Lan ^c   Monteagudo, Edith ^a   Marsh, Donald J ^c   Sinharoy, Ranabir ^c   Bianchi, Elisabetta ^a   Pessi, Antonello ^a,g  

^a IRBM   (Italy)

^b BASF   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Merck Serono SpA   (Italy)

^e Diasorin SpA   (Italy)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^g PeptiPharma   (Italy)

Author keywords

GLP 1 receptor agonists; GLP 1 glucagon receptor dual agonists; Oxyntomodulin

Indexed keywords

CHOLEST 5 EN 3 YL 1 BROMO 2 OXO 6,9,12,15 TETRAOXA 3 AZAOCTADECAN 18 OATE; CHOLEST 5 EN 3 YL BROMOACETATE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; OXYNTOMODULIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; DRUG POTENCY; ENZYME DEGRADATION; IN VIVO STUDY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN STABILITY; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIPEPTIDYL PEPTIDASE 4; EATING; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OBESITY; OXYNTOMODULIN; PEPTIDES; WEIGHT LOSS;

CAPITO; MUS;

EID: 79952464908     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1328     Document Type: Article

References (34)

1. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
2. Knop FK, Vilsboll T, Larsen S, Madsbad S, Holst JJ, Krarup T. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care 2003; 26: 2581-2587.
3. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat. Rev. Drug Discov. 2010; 9: 267-268.
4. Holst JJ. Enteroglucagon. Annu. Rev. Physiol. 1997; 59: 257-271.
5. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul. Pept. 1988; 21: 151-166.
6. Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993; 133: 631-638.
7. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142: 4244-4250.
8. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546-558.
9. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008; 149: 5670-5678.
10. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am. J. Physiol. Endocrinol. Metab. 2002; 283: E1173-E1177.
11. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695.
12. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395.
13. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) 2006; 30: 1729-1736.
14. Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regul. Pept. 1990; 31: 41-52.
15. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J. Biol. Chem. 2003; 278: 22418-22423.
16. Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG, Ghatei MA, Bloom SR. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 2009; 150: 1712-1722.
17. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschop MH. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 2009; 5: 749-757.
18. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capitò E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58: 2258-2266.
19. Inooka H, Ohtaki T, Kitahara O, Ikegami T, Endo S, Kitada C, Ogi K, Onda H, Fujino M, Shirakawa M. Conformation of a peptide ligand bound to its G-protein coupled receptor. Nat. Struct. Biol. 2001; 8: 161-165.
20. Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J. Endocrinol. 2004; 180: 379-388.
21. Gallwitz B, Ropeter T, Morys-Wortmann C, Mentlein R, Siegel EG, Schmidt WE. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul. Pept. 2000; 86: 103-111.
22. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41: 271-278.
23. Runge S, Gram C, Bräuner-Osborne H, Madsen K, Knudsen LB, Wulff BS. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J. Biol. Chem. 2003; 278: 28005-28010.
24. Mahalakshmi R, Balaram P. Non-protein amino acids in the design of secondary structure scaffolds. Methods Mol. Biol. 2006; 340: 71-94.
25. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thogersen H, Wilken M, Johansen NL. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 2007; 50: 6126-6132.
26. Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD, Pessi A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA 2009; 106: 5801-5806.
27. Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Knolker HJ, Simons K. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 2008; 320: 520-523.
28. Chini B, Parenti M. G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there?. J. Mol. Endocrinol. 2004; 32: 325-338.
29. Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, Reedtz-Runge S. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 2010; 285: 723-730.
30. Bader R, Zerbe O. Are hormones from the neuropeptide Y family recognized by their receptors from the membrane-bound state? ChemBiochem 2005; 6: 1520-1534.
31. Schwyzer R. Membrane-assisted molecular mechanism of neurokinin receptor subtype selection. EMBO J. 1987; 6: 2255-2259.
32. Seelig A, Alt T, Lotz S, Holzemann G. Binding of substance P agonists to lipid membranes and to the neurokinin-1 receptor. Biochemistry 1996; 35: 4365-4374.
33. Rink H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Lett. 1987; 28: 3787-3789.
34. Sole NA, Barany G. Optimization of solid-phase synthesis of [Ala8]-dynorphin A. J. Org. Chem. 1992; 57: 5399-5403.